September 14, 2022
Role of Risk Assessment in Advanced Technologies | September 14, 2022 11:00 - 12:30 EDT
Talks in this DC Discussion Group will describe some of these experiences and efforts by industry and regulators to better ensure the quality of biological products. Jean-Pol Cassart, from GlaxoSmithKline Belgium and Kevin Carrick from US Pharmacopeia, USA will discuss the role of risk assessment in advanced technologies; a panel discussion with live attendee interaction will follow. This virtual discussion group is free to attend, but you must register in advance. Registration will close September 13, 2022.
Jean-Pol Cassart from GlaxoSmithKline Pharmaceuticals s.a/n.v, Belgium’s Viral Safety Program will address the investigation into PCV-1 contamination of GSK’s rotavirus vaccine and the development of their viral risk assessment and response plan.
Kevin Carrick from US Pharmacopeia, USA will discuss the 2008 heparin contamination.